Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms (Protocol No.: THVD-201-002).
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Tolterodine/pilocarpine (Primary) ; Tolterodine
- Indications Overactive bladder; Urge incontinence
- Focus Therapeutic Use
- 04 Apr 2013 Status changed from recruiting to completed according to a TheraVida media release.
- 02 Apr 2013 Results published in a TheraVida Media Release.
- 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History